All articles tagged with #bundibugyo
The Ebola outbreak in the Democratic Republic of Congo has surpassed 8,400 confirmed cases and 4,000 deaths, driven by the rare Bundibugyo virus. While a new treatment center is being built in Mangala, local health workers argue the response was delayed, allowing the virus to spread rapidly across seven provinces.
Congo's Ebola outbreak has killed 4,018 people from 8,300 confirmed cases, becoming the fastest-growing outbreak in history. Containment is hindered by unpaid health worker strikes, community mistrust, and the burning of a treatment center, while the WHO warns it may surpass the 2014-2016 West Africa toll.
The World Health Organization confirmed that the Bundibugyo strain of Ebola has spread to two new health zones in the Democratic Republic of Congo, bringing the total affected areas to 63 across seven provinces. As of September 23, the country reported 7,890 confirmed cases and 3,799 deaths, resulting in a case-fatality rate of nearly 48 percent. The outbreak, which began in May, remains centered in Ituri province but is expanding into North Kivu and border regions. WHO Director-General Tedros Adhanom Ghebreyesus highlighted that armed conflict and displacement are hindering contact tracing and access to affected communities. While no approved vaccine exists for this specific strain, clinical trials are underway, and the Ervebo vaccine, designed for the Zaire strain, is being used under compassionate use programs for frontline workers.
The Ebola outbreak in the Democratic Republic of Congo has surged to 6,041 confirmed cases with about 2,911 deaths, driven by the fast-spreading Bundibugyo strain for which no vaccine or treatment exists. Most cases are in eastern provinces where insecurity, displacement and weak health services impede containment, while aid groups cite logistics disruptions and frontline strikes over unpaid wages; Uganda has since been declared Ebola-free after 42 days with no new cases.
Congo has received 16,250 doses of the Ervebo Ebola vaccine from the WHO and partners as part of a 70,000-dose rollout to combat the fastest Ebola outbreak on record caused by the Bundibugyo virus; the vaccine—while not yet specific to Bundibugyo—may offer protection and is intended to help contain the spread as Congo reports 5,375 confirmed cases across six provinces and 2,557 deaths, with more doses expected early next week. Containment challenges include ongoing armed conflict, attacks on health workers and facilities, displacement, and weak infrastructure.
A Nature Medicine study shows the current Ebola outbreak in the Democratic Republic of the Congo began with a new animal-to-human spillover of the Bundibugyo virus, then spread mainly through human-to-human transmission. With more than 4,400 cases and about 2,000 deaths, it’s the fastest-moving outbreak on record and could become the deadliest; there are no licensed vaccines or virus-specific treatments for this strain yet, though experimental options are in development. WHO projects the outbreak could peak within months and last up to a year under various scenarios, as efforts focus on expanded diagnostics, genomic sequencing, PPE for frontline workers, and cross-border measures amid challenges like health worker strikes and misinformation.
A Nature Medicine study analyzing samples from 22 patients finds a new Bundibugyo Ebola virus variant linked to a fresh animal-to-human spillover in the Congo-Uganda outbreak; the strain is genetically distinct from earlier Bundibugyo outbreaks, and Uganda cases are connected to the Congo event, though the exact animal source remains unidentified. There is no approved vaccine, but candidates are in development. The study highlights the value of broader testing and virus sequencing for early outbreak detection, as the outbreak has surpassed 2,000 deaths with about 4,381 confirmed cases to date.
The Bundibugyo strain of Ebola in eastern Congo has killed more than 2,000 people and infected over 4,300, with the strain being genetically distinct from the 2014 Zaire variant, limiting the effectiveness of existing therapies and vaccines. Despite the severity, the risk to Americans remains very low since transmission requires close contact with bodily fluids; researchers are pursuing new treatments and vaccines, including mRNA-based approaches, and international support is essential to containment.
Congo’s Bundibugyo Ebola outbreak — the fastest-growing on record — has killed about 2,000 people (2,011 deaths among 4,381 confirmed cases) as it spreads across five eastern provinces near South Sudan, Uganda and Rwanda. It is the second-largest Ebola outbreak in history, with a case-fatality rate around 45.9% and no approved vaccines or treatments for Bundibugyo. The outbreak began earlier than officially declared (likely February) and responders face challenges from ongoing conflict, poor infrastructure, and misinformation, while early cases were sometimes misclassified as malaria or typhoid; vaccines are in clinical trials, and authorities have restricted gatherings to slow transmission.
The Democratic Republic of Congo's Ebola outbreak—the fastest-growing on record—started in February, months before it was officially declared in mid-May. WHO sequencing suggests early cases were misattributed to malaria and typhoid. With 4,200 confirmed cases and at least 1,900 deaths, the Bundibugyo strain has no licensed vaccines or treatments, delaying response. WHO is pursuing Ervebo vaccine trials while Bundibugyo vaccines are in early development, amid challenges from strikes, conflict, misinformation, and displacement.
The Democratic Republic of the Congo’s Ebola outbreak has killed 1,707 people and infected 3,802, with most cases in Ituri province. The Bundibugyo strain has no approved vaccines or treatments yet, but the WHO says trials of experimental therapies and vaccines are moving faster than in prior outbreaks. More than 17,000 contacts are being monitored, though the response is hampered by violence, mistrust, and funding gaps; healthcare workers are among those infected. Uganda has declared Ebola-free, and this outbreak is the second-largest and fastest-growing on record.
Eastern Congo’s Ebola outbreak linked to the Bundibugyo virus has killed 1,521 people out of 3,442 cases, marking the fastest-growing surge as response efforts are hampered by backlogs, mistrust, and violence; Ituri province accounts for the vast majority of cases, with attacks on health facilities and limited vaccines/treatments complicating containment, while the WHO says global risk is low but Congo’s risk is very high and neighboring Uganda has declared itself Ebola-free.
DR Congo is facing its largest Ebola outbreak on record, caused by the Bundibugyo strain, with 3,605 confirmed cases and 1,587 deaths (about 44% fatal) as of July 30, 2026, surpassing the 2018–2020 outbreak. No approved vaccine or treatment exists yet, though vaccines are in development in the UK and Singapore. The outbreak is intensifying, with the highest weekly totals (567 cases, 296 deaths) and is hampered by insecurity, displacement, and cross-border movement. The epicenter is Ituri Province, with spread to North and South Kivu and cases in Uganda; a few cases have been treated in Europe. WHO notes ongoing transmission and progress on vaccine development as trials proceed."
DRC’s Ebola outbreak has 3,442 cases and 1,521 deaths (up about 50% in a week), with no vaccine for the Bundibugyo strain and containment hampered by ongoing conflict, limited access, reporting backlogs, and community mistrust; Ituri province accounts for about 90% of cases, while unsafe handling of bodies and attacks on health facilities fuel spread, though WHO says global risk remains low.
Ebola deaths in the Democratic Republic of Congo have risen to at least 1,309 with confirmed cases near 2,973, marking a rapid surge in what experts call the fastest-spreading outbreak yet. The Bundibugyo variant, which has no approved vaccines, is driving the spread in a conflict-affected region, straining healthcare workers and facilities amid shortages and strikes. A rapidly developed experimental vaccine is in early trials, while officials urge immediate action and better access for responders to curb the crisis.